Drug intelligence / Profile preview

XJ103

Development stage: Phase 1
Lead developer: Xingji Biology
Modality: Recombinant Proteins and Enzymes
Administration: Injection

Overview

XJ103 is an investigational drug candidate developed by Xingji Biology (Suzhou) Co., Ltd. It is currently in Phase 1 clinical trials, with the primary objective of evaluating its safety and tolerability as a single-dose injection in healthy subjects. Secondary objectives include assessment of pharmacokinetics and immunogenicity, while exploratory objectives focus on pharmacodynamics. The main therapeutic area under investigation for XJ103 is infectious diseases, specifically pneumococcal disease. The study design is randomized, double-blind, placebo-controlled, and single-ascending dose.

Beyond the preview

Go deeper on XJ103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XJ103.

Explore the full profile